Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 25,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average cost of $20.96 per share, for a total transaction of $524,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Xencor, Inc. (XNCR) opened at 19.94 on Monday. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The company’s market capitalization is $935.70 million. The company has a 50-day moving average price of $22.56 and a 200 day moving average price of $23.00.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The business had revenue of $13.34 million during the quarter, compared to the consensus estimate of $8.15 million. Equities research analysts anticipate that Xencor, Inc. will post ($1.17) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/21/insider-buying-xencor-inc-xncr-major-shareholder-buys-524000-00-in-stock.html.

Several equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research report on Wednesday, May 10th. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $29.33.

Several large investors have recently bought and sold shares of XNCR. Equitec Specialists LLC acquired a new position in Xencor during the second quarter worth about $116,000. SG Americas Securities LLC increased its position in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares in the last quarter. Legal & General Group Plc increased its position in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Airain ltd acquired a new position in Xencor during the first quarter worth about $213,000. Finally, Citadel Advisors LLC acquired a new position in Xencor during the second quarter worth about $224,000. Institutional investors and hedge funds own 73.53% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.